BreakthroughT1D’s Spring Virtual TON Summit: What’s in it for You? Everything!
Find out why the event is “worth every second of your Saturday to attend.”
COVID-19 and Type 1: School and Employment Rights, from a Lawyer
To help you traverse the school and employment rights with type 1 diabetes, Breakthrough T1D had a Facebook Live event with attorney Daniel Phelan, J.D.
Bench to Bedside: Breakthrough T1D-nPOD Conference
The 13th nPOD Annual Meeting was held February 22-24, 2021, and featured some of the most world-renowned diabetes investigators.
Investigations by Leading Immune-Mediated Disease Research Organizations
Breakthrough T1D has partnered with the Lupus Research Alliance and the National Multiple Sclerosis Society to advance the understanding of autoimmunity.
Breakthrough T1D Launches Third Center of Excellence in New England
The Breakthrough T1D New England Center of Excellence will focus on protecting the stem cell-derived beta cells from rejection by the immune system after transplantation.
The Girl Who Won’t Back Down From Type 1 Diabetes
My daughter Gia was playing organized sports for the first time. A leading scorer in basketball like her dad, a 14-year NBA veteran, she was excited to play. Until there was a change. Gia was lethargic. She vomited every day, had an unquenchable thirst, and started wetting the bed. This continued for a couple of […]
She Had a Wish: Donate to Science
When Cheryl Diderich died, her husband knew she wanted to live on through his gift of $1.2 million to Breakthrough T1D, to fund the research of Jon Odorico, M.D.
T1D Voices: Reagan’s Story Is Our Story
T1D Champion Reagan Moore shares her T1D journey, her hopes for the future, and why she loves her insulin pump.
Can a Psoriasis Drug Halt or Reverse Type 1 Diabetes?
Type 1 diabetes is one of the only major autoimmune diseases that doesn't have a disease-modifying therapy. A Breakthrough T1D clinical trial is aiming to change that.
Special Diabetes Program (SDP) Renewed for Three Years!
One of Breakthrough T1D’s top legislative priorities has been achieved with the enactment of a three-year renewal of the Special Diabetes Program (SDP). The program, now funded until September 30, 2023 at $150 million per year, will enable researchers to build upon the momentum in type 1 diabetes (T1D) to date and explore new opportunities […]
